期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到1,820篇文章
< 1 2 … 91 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Multiple clear-cell sarcomas of small intestine with parotid gland metastasis: A case report 认领 引用
1
作者 Hao Su Wen-Sheng Liu +3 位作者 Wen-Hao Ren Peng Wang Lei Shi Hai-Tao Zhou 《World Journal of Gastroenterology》 SCIE CAS 2017年第12期2258-2265,共8页
Clear-cell sarcoma is a rare, malignant soft tissue tumor that displays melanocytic differentiation with a distinct molecular profile. It is rarely localized in the gastrointestinal tract. Herein we reported a case of... Clear-cell sarcoma is a rare, malignant soft tissue tumor that displays melanocytic differentiation with a distinct molecular profile. It is rarely localized in the gastrointestinal tract. Herein we reported a case of multiple synchronous clear-cell sarcomas of the gastrointestinal tract with parotid gland metastasis. A 51-year-old male patient presented with a growing painless mass under the right ear. A preoperative positron emission tomography/computed tomography showed multiple intestinal masses and a mass in the right parotid with increased glucose uptake, and he underwent operative treatment with resection of three tumors in the jejunum and ileum and then received a right parotidectomy. Postoperative pathological examination showed that cells in the intestinal tumor were consistent with clear-cell sarcoma of the gastrointestinal tract, and the malignant cells in the parotid gland were similar to the intestinal tumor. Immunohistochemical studies revealed positive expression of HMB-45, Melan-A, and S-100. EWSR1 gene fusion transcripts were undetectable by fluorescence in situ hybridization. 展开更多
关键词 Clear-cell sarcomas Clear-cell sarcomas of the gastrointestinal tract Parotid gland metastasis Immunohistochemistry
暂未订购 下载PDF
Identification of Prognostic Related Hub Genes in Clear-Cell Renal Cell Carcinoma via Bioinformatical Analysis 认领 引用
2
作者 Ping Jiang Taotao Sun +6 位作者 Cunwu Chen Renshu Huang Zhimei Zhong Xinjian Lou Gang Liu Lin Wang Ruihua Zuo 《Chinese Medical Sciences Journal》 CAS CSCD 2021年第2期127-134,共8页
Objective To identify new genes that correlate with prognosis of clear-cell renal cell carcinoma(ccRCC)via bioinformatics analysis.Methods The gene expression profiles of 62 ccRCC and 54 normal kidney tissues were ava... Objective To identify new genes that correlate with prognosis of clear-cell renal cell carcinoma(ccRCC)via bioinformatics analysis.Methods The gene expression profiles of 62 ccRCC and 54 normal kidney tissues were available from the Gene Expression Omnibus database:GSE12606,GSE36895 and GSE66272.The differentially expressed genes were screened with GEO2R and J Venn online tools.Functional annotation including Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)was applied to identify the possible function of the hub genes involved in prognosis of ccRCC.In protein protein interaction network(PPI network),the STRING online tool was used to visualize the network of the differentially expressed genes,and the core gene was selected by MCODE App in Cytoscape software.Finally,GEPIA Survival Plot was performed to assess genes associated with worse survival.Results We totally found 648 diflerentially expressed genes,including 222 up-regulated genes and 426 down-regulated genes.PPI network showed that in 28 up-regulated genes 7(CCNE2,CDK1,CDC6,CCNB2,BUB1,TTK and PTTG1)enriched in cell cycle and 4 genes(CCNE2,CDK1,CCNB2 and RRM2)enriched in p53 signaling pathway.GEPIA Survival Plot assay revealed that ccRCC patients carrying CDK1,CCNB2,RRM2t BUB1,and PTTG1 had a worse survival.GEPIA Box Plot showed that BUB1,CCNB2,PTTG1,and RRM2 were over expressed in the ccRCC tissues in contrast to the normal tissues(P<O.OS).Conclusion ccRCC patients with the four up-regulated differentially expressed genes including BUB1,CCNB2,PTTG1,and RRM2 might manifest a poor prognosis. 展开更多
关键词 clear-cell renal cell carcinoma bioinformatical analysis differentially expressed genes
暂未订购 下载PDF
Case of clear-cell hepatocellular carcinoma that developed in the normal liver of a middle-aged woman 认领 引用 被引量：22
3
作者 Atsushi Takahashi Hironobu Saito +7 位作者 Yukiko Kanno Kazumichi Abe Junko Yokokawa Atsushi Irisawa Akira Kenjo Takuro Saito Mitsukazu Gotoh Hiromasa Ohira 《World Journal of Gastroenterology》 SCIE CAS 2008年第1期129-131,共3页
A 36-year-old woman was admitted to our department for close examination of a liver tumor that was found during a medical checkup. Abdominal US, CT and MRI showed a tumor in segment 7 (S7) of the liver. Although imagi... A 36-year-old woman was admitted to our department for close examination of a liver tumor that was found during a medical checkup. Abdominal US, CT and MRI showed a tumor in segment 7 (S7) of the liver. Although imaging suggested hepatocellular carcinoma, laboratory tests showed no abnormality in liver function, hepatitis virus markers were negative, and tumor markers including protein induced by vitamin K absence or antagonist Ⅱ (PIVKA-Ⅱ), α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) were all within normal ranges. Upon aspiration biopsy of the liver, the histopathological diagnosis was moderately differentiated hepatocellular carcinoma. Therefore, right hepatectomy was performed. Although a part of the tumor was necrotic, about 60% of the viable part showed a clear-cell variant. Consequently, it was diagnosed as clear-cell hepatocellular carcinoma. It was noted that the background liver tissue was normal. This case is worthy of reporting because development of clear-cell hepatocellular carcinoma in the normal liver of a middle-aged woman is rarely seen. 展开更多
关键词 Clear-cell hepatocellular carcinoma Liver Middle-aged
暂未订购 下载PDF
Clear-cell variant of calcifying epithelial odontogenic tumor (Pindborg tumor) in the mandible 认领 引用 被引量：1
4
作者 Ching-Yi Chen Chung-Wei Wu +2 位作者 Wen-Chen Wang Li-Min Lin Yuk-Kwan Chen 《International Journal of Oral Science》 SCIE CAS CSCD 2013年第2期115-119,共5页
We present an uncommon case （female patient aged 59 years） of the clear-cell variant of calcifying epithelial odontogenic tumor （CEOT） （also known as Pindborg tumor） in the mandible. The clinical characteristics... We present an uncommon case （female patient aged 59 years） of the clear-cell variant of calcifying epithelial odontogenic tumor （CEOT） （also known as Pindborg tumor） in the mandible. The clinical characteristics and probable origins of the clear tumor cells of previously reported cases of clear-cell variant of intraosseous CEOT are also summarized and discussed. 展开更多
关键词 calcifying epithelial odontogenic tumor clear cell Pindborg tumor
暂未订购 下载PDF
Sorafenib Acts through VEGFR-2 Inhibition in a Metastatic Clear-Cell Sarcoma of the Kidney 认领 引用 被引量：1
5
作者 Tu V. Dao Thuan V. Tran +4 位作者 Christophe Lebœuf Morad El-Bouchtaoui Jérôme Verine Anne Janin Guilhem Bousquet 《Journal of Cancer Therapy》 2016年第7期487-493,共7页
We report here the case of a young patient with metastatic clear-cell sarcoma of the kidney resistant to standard chemotherapy, and with complete response under sorafenib treatment. The remarkable response of her tumo... We report here the case of a young patient with metastatic clear-cell sarcoma of the kidney resistant to standard chemotherapy, and with complete response under sorafenib treatment. The remarkable response of her tumor to sorafenib led us to study sorafenib molecular targets in the metastatic tissue. Background: Biomarkers predicting response to anti-angiogenic tyrosine kinase inhibitors remain to be identified. Methods and Findings: In this paper, we studied the molecular targets of sorafenib in the lung metastasis of a kidney clear-cell sarcoma. In a patient with complete response under sorafenib treatment, we showed high VEGFR2 expression by tumor endothelial cells from the lung metastasis. Conclusion: The original mechanistic results that we obtained using immunostainings and quantitative RT-PCR on laser-microdissected tumor endothelial cells have a direct application in daily clinical practice: metastatic tumors with a large angiogenic component should be tested for VEGFRs expression to consider anti-angiogenic tyrosine kinase inhibitor treatments. 展开更多
关键词 Tyrosine-Kinase Inhibitor VEGFR2 Metastases Clear-Cell Sarcoma of the Kidney
暂未订购 下载PDF
Artificial intelligence-based non-invasive tumorsegmentation, grade stratification and prognosisprediction for clear-cell renal-cell carcinoma 认领 引用 被引量：5
6
作者 Siteng Chen Dandan Song +11 位作者 Lei Chen Tuanjie Guo Beibei Jiang Aie Liu Xianpan Pan Tao Wang Heting Tang Guihua Chen Zhong Xue Xiang Wang Ning Zhang Junhua Zheng 《Precision Clinical Medicine》 2023年第3期148-157,共10页
Due to the complicated histopathological characteristics of clear-cell renal-cell carcinoma(ccRcC),non-invasive prognosis before operative treatment is crucial in selecting the appropriate treatment.A total of 126345 ... Due to the complicated histopathological characteristics of clear-cell renal-cell carcinoma(ccRcC),non-invasive prognosis before operative treatment is crucial in selecting the appropriate treatment.A total of 126345 computerized tomography(cT)images from four independent patient cohorts were included for analysis in this study.We propose a V Bottieneck multi-resolution and focus-organ network(VB-MrFo-Net)using a cascade framework for deep learning analysis.The VB-MrFo-Net achieved better performance than VB-Net in tumor segmentation,with a Dice score of 0.87.The nuclear-grade prediction model performed best in the logistic regression classifier,with area under curve values from 0.782 to 0.746.Survival analysis revealed that our prediction model could significantly distinguish patients with high survival risk,with a hazard ratio(HR)of 2.49[95%confidence interval(CI):1.13-5.45,P=0.023]in the General cohort.Excellent performance had also been verified in the Cancer Genome Atlas cohort,the Clinical Proteomic Tumor Analysis Consortium cohort,and the Kidney Tumor Segmentation Challenge cohort,with HRs of 2.77(95%CI:1.58-4.84,P=0.0019),3.83(95%CI:1.22-11.96,P=0.029),and 2.80(95%CI:1.05-7.47,P=0.025),respectively.In conclusion,we propose a novel VB-MrFo-Net for the renal tumor segmentation and automatic diagnosis of ccRcc.The risk stratification model could accurately distinguish patients with high tumor grade and high survival risk based on non-invasive CT images before surgical treatments,which couid provide practical advicefordecidingtreatmentoptions. 展开更多
关键词 deep learning diagnosis non-invasive prognosis prediction clear-cell renal-cell carcinoma
Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma 认领 引用 被引量：3
7
作者 Yan Song Jing Huang +1 位作者 Ling Shan Hong-Tu Zhang 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第15期2026-2033,共8页
Background：Vascular endothelial growth factor-targeted agents are standard treatments in advanced clear-cell renal cell carcinoma （ccRCC）,but biomarkers of activity are lacking.The aim of this study was to investig... Background：Vascular endothelial growth factor-targeted agents are standard treatments in advanced clear-cell renal cell carcinoma （ccRCC）,but biomarkers of activity are lacking.The aim of this study was to investigate the association of Von Hippel-Lindau （VHL） gene status,vascular endothelial growth factor receptor （VEGFR） or stem cell factor receptor （KIT） expression,and their relationships with characteristics and clinical outcome of advanced ccRCC.Methods：A total of 59 patients who received targeted treatment with sunitinib or pazopanib were evaluated for determination at Cancer Hospital and Institute,Chinese Academy of Medical Sciences between January 2010 and November 2012.Paraffin-embedded tumor samples were collected and status of the VHL gene and expression of VEGFR and KIT were determined by VHL sequence analysis and immunohistochemistry.Clinical-pathological features were collected and efficacy such as response rate and Median progression-free survival （PFS） and ovcrall survival （OS） were calculated and then compared based on expression status.The Chi-square test,the KaplanMeier method,and the Lon-rank test were used for statistical analyses.Results：Of 59 patients,objective responses were observed in 28 patients （47.5%）.The median PFS was 13.8 months and median OS was 39.9 months.There was an improved PFS in patients with the following clinical features：Male gender,number of metastatic sites 2 or less,VEGFR-2 positive or KIT positive.Eleven patients （18.6%） had evidence of VHL mutation,with an objective response rate of 45.5%,which showed no difference with patients with no VHL mutation （47.9%）.VHL mutation status did not correlate with either overall response rate （P =0.938） or PFS （P =0.277）.The PFS was 17.6 months and 22.2 months in VEGFR-2 positive patients and KIT positive patients,respectively,which was significantly longer than that of VEGFR-2 or KIT negative patients （P =0.026 and P =0.043）.Conclusion：VHL mutation status could not predict the efficacy of sunitinib or pazopanib.Further investigation of VHL/VEGFR pathway components is needed. 展开更多
关键词 Clear-cell Renal Cell Carcinoma Kidney Cancer Prognosis Vascular Endothelial Growth Factors Von Hippel-Lindau
NAT10-mediated ac 4 C-modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear-cell renal cell carcinoma by attenuating YWHAE-driven cytoplasmic retention of YAP1 认领 引用 被引量：3
8
作者 Daojia Miao Jian Shi +4 位作者 Qingyang Lv Diaoyi Tan Chuanyi Zhao Zhiyong Xiong Xiaoping Zhang 《Cancer Communications》 SCIE 2024年第3期361-383,共23页
Background:Lymphatic metastasis is one of the most common metastatic routes and indicates a poor prognosis in clear-cell renal cell carcinoma(ccRCC).N-acetyltransferase 10(NAT10)is known to catalyze N4-acetylcytidine(... Background:Lymphatic metastasis is one of the most common metastatic routes and indicates a poor prognosis in clear-cell renal cell carcinoma(ccRCC).N-acetyltransferase 10(NAT10)is known to catalyze N4-acetylcytidine(ac4C)modification of mRNA and participate in many cellular processes.However,its role in the lymphangiogenic process of ccRCC has not been reported.This study aimed to elucidate the role of NAT10 in ccRCC lymphangiogenesis,providing valuable insights into potential therapeutic targets for intervention.Methods:ac4C modification and NAT10 expression levels in ccRCC were assessed using public databases and clinical samples.Functional investigations involved manipulating NAT10 expression in cellular and mouse models to study its role in ccRCC.Mechanistic insights were gained through a combination of RNA sequencing,mass spectrometry,co-immunoprecipitation,RNA immuno-precipitation,immunofluorescence,and site-specific mutation analyses.Results:We found that ac4C modification and NAT10 expression levels increased in ccRCC.NAT10 promoted tumor progression and lymphangiogene-sis of ccRCC by enhancing the nuclear import of Yes1-associated transcriptional regulator(YAP1).Subsequently,we identified ankyrin repeat and zinc fin-ger peptidyl tRNA hydrolase 1(ANKZF1)as the functional target of NAT10,and its upregulation in ccRCC was caused by NAT10-mediated ac4C modifi-cation.Mechanistic analyses demonstrated that ANKZF1 interacted with tyro-sine 3-monooxygenaseryptophan 5-monooxygenase activation protein epsilon(YWHAE)to competitively inhibit cytoplasmic retention of YAP1,leading to transcriptional activation of pro-lymphangiogenic factors.Conclusions:These results suggested a pro-cancer role of NAT10-mediated acetylation in ccRCC and identified the NAT10/ANKZF1/YAP1 axis as an under-reported pathway involving tumor progression and lymphangiogenesis in ccRCC. 展开更多
关键词 clear-cell renal cell carcinoma N4-acetylcytidine N-acetyltransferase 10 YAP1 nuclear import
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma 认领 引用 被引量：1
9
作者 Monica Sheila Chatwal Jad Chahoud Philippe E.Spiess 《Cancer Drug Resistance》 CAS 2023年第2期314-326,共13页
Renal-cell carcinoma(RCC)remains a leading cause of cancer-related mortality worldwide.Though newer therapeutic combinations of immune checkpoint inhibitors and targeted therapies have greatly improved outcomes,resist... Renal-cell carcinoma(RCC)remains a leading cause of cancer-related mortality worldwide.Though newer therapeutic combinations of immune checkpoint inhibitors and targeted therapies have greatly improved outcomes,resistance to these therapies is becoming a challenge for long-term control.Mechanisms of resistance have been explored in a variety of solid tumors,including RCC.Based upon our review of the current literature on the mechanisms of resistance to immunotherapies for the management of metastatic clear-cell renal cell carcinomas(mccRCC),the ensuing conclusions have been made:The management of mccRCC has progressed substantially with the advent of checkpoint inhibitors and targeted oral therapies,alone and/or in combination.Nevertheless,innate or developed resistance to these therapies remains an ongoing challenge,particularly to immune checkpoint inhibitors(ICIs).Several of the known mechanisms of resistance have been well defined,but recent progression in cellular therapies helps to expand the armamentarium of potential combination options that may overcome these modes of resistance and improve long-term disease control and survival for an otherwise dismal disease.In the ensuing review and update of the literature on the mechanisms of resistance to immunotherapies in mccRCC,we have revisited the known resistance mechanisms of immunotherapies in metastatic clear-cell RCC and explored ongoing and future strategies to overcome them. 展开更多
关键词 Metastatic clear-cell renal-cell carcinoma immune therapy checkpoint inhibitor resistance chimeric antigen receptor T-cell therapy
Ⅱ型子宫内膜癌的分子特征及靶向治疗研究进展 认领 引用 被引量：1
10
作者 谢云凯 孔为民 《现代肿瘤医学》 CAS 2026年第6期1034-1038,共5页
子宫内膜癌(endometrial carcinoma,EC)是妇科常见恶性肿瘤,其中以Ⅱ型子宫内膜癌恶性程度高。该病理类型内膜癌相对少见,且肿瘤生物学行为及分子特征与子宫内膜腺癌存在较大差异,因此临床上Ⅱ型子宫内膜癌的预后较差。Ⅱ型子宫内膜癌... 子宫内膜癌(endometrial carcinoma,EC)是妇科常见恶性肿瘤,其中以Ⅱ型子宫内膜癌恶性程度高。该病理类型内膜癌相对少见,且肿瘤生物学行为及分子特征与子宫内膜腺癌存在较大差异,因此临床上Ⅱ型子宫内膜癌的预后较差。Ⅱ型子宫内膜癌的治疗主要依靠手术及放化疗,但对于高危型及复发患者效果较差,目前临床上针对Ⅱ型子宫内膜癌缺乏有效的靶向治疗药物。分子特征在子宫内膜癌的诊断和靶向药物的研发应用中发挥着重要的指导作用,Ⅱ型子宫内膜癌中存在多种肿瘤相关基因的突变,目前针对这些基因突变而进行的基础和临床研究众多。该文对Ⅱ型子宫内膜癌中两种最为常见的子宫浆液性癌和透明细胞癌的分子生物学特征进行阐述,并结合分子特征对该两种病理类型子宫内膜癌的靶向治疗相关基础和临床研究进行探讨。 展开更多
关键词 Ⅱ型子宫内膜癌 靶向治疗 分子分型 子宫浆液性癌 子宫透明细胞癌
暂未订购 下载PDF
E2F2在肾透明细胞癌中的高表达及其与预后和肿瘤免疫微环境的相关性 认领 引用
11
作者 瞿根义 龙朝辉 +4 位作者 黄文琳 阳光 汤乘 徐勇 银利 《现代泌尿外科杂志》 CAS 2026年第2期172-181,共10页
目的探讨转录因子E2F2在肾透明细胞癌(ccRCC)中的表达特征、对预后的影响及在肿瘤免疫微环境中的潜在作用,并通过临床样本和功能实验验证。方法从癌症基因组图谱(TCGA)数据库获取ccRCC患者RNA测序数据及临床资料,基因表达综合数据库(GEO... 目的探讨转录因子E2F2在肾透明细胞癌(ccRCC)中的表达特征、对预后的影响及在肿瘤免疫微环境中的潜在作用,并通过临床样本和功能实验验证。方法从癌症基因组图谱(TCGA)数据库获取ccRCC患者RNA测序数据及临床资料,基因表达综合数据库(GEO)下载GSE53757和GSE66272作为外部验证集,比较ccRCC组织与正常组织中E2F2的表达差异。分析E2F2表达水平与临床及病理特征的关系。采用Kaplan-Meier(KM)生存分析以及log-rank检验评估E2F2对总体生存期(OS)、无进展生存期(PFS)和疾病特异性生存期(DSS)的影响。采用受试者工作特征(ROC)曲线评估E2F2对患者1、3、5年生存状态的预后预测效能。采用基因富集分析(GSEA)E2F2相关信号通路。采用ESTIMATE与CIBERSORT算法评估E2F2表达水平与肿瘤免疫细胞浸润及免疫微环境的关系。收集中南大学湘雅医学院附属株洲医院20例经术后病理确诊的ccRCC患者的肿瘤组织及其配对癌旁正常组织,免疫组织化学检测E2F2蛋白表达水平。采用人ccRCC细胞系786-O进行细胞功能实验,使用shRNA干扰E2F2表达(构建shE2F2#1和shE2F2#2稳定转染株),通过实时荧光定量逆转录聚合酶链反应(qRT-PCR)与蛋白质印迹法分别验证干扰效率。采用MTT、克隆形成和Transwell迁移实验验证E2F2对ccRCC细胞生物学行为的影响。结果E2F2在ccRCC组织中显著高表达(外部验证集结果与之相同),E2F2高表达与组织学分级、临床分期、TNM分期显著相关(P<0.05)。KM生存分析显示,E2F2高表达组较低表达组患者的OS(P=0.019)、PFS(P=0.036)和DSS(P<0.001)均更短。E2F2预测ccRCC患者1、3、5年生存情况的ROC曲线下面积分别为0.844、0.851、0.815。GSEA结果显示,E2F2低表达组富集于多种代谢相关通路,高表达组则与免疫功能通路相关。免疫分析显示,E2F2高表达水平与肿瘤免疫评分升高、免疫细胞比例升高、肿瘤突变负荷升高及更强的免疫治疗响应能力相关。免疫组化结果显示,ccRCC组织中E2F2免疫评分显著高于癌旁正常组织(P<0.05)。细胞实验显示,E2F2沉默可显著抑制ccRCC细胞的增殖、克隆形成及迁移能力。结论E2F2在ccRCC中高表达,可能通过调控免疫微环境参与肿瘤发生与进展,其表达水平与患者预后密切相关,有望成为ccRCC潜在的预后生物标志物及免疫治疗靶点。 展开更多
关键词 E2F2 肾透明细胞癌 预后 免疫浸润 基因富集分析(GSEA) 免疫治疗
暂未订购 下载PDF
绞股蓝皂苷L/LI诱导肾透明细胞癌细胞凋亡及自噬的分子机制研究 认领 引用
12
作者 刘慧 热增才旦 +2 位作者 于佳慧 朴香兰 李修明 《辽宁中医杂志》 CAS 北大核心 2026年第4期157-162,I0002,共6页
目的该研究旨在探讨绞股蓝皂苷L Gypenoside L(Gyp L)和绞股蓝皂苷LI Gypenoside LI(Gyp LI)对肾透明细胞癌细胞增殖、凋亡和自噬的影响及其作用机制。方法采用网络药理学及分子对接技术预测有效成分与关键作用靶点的结合,对关键靶点和... 目的该研究旨在探讨绞股蓝皂苷L Gypenoside L(Gyp L)和绞股蓝皂苷LI Gypenoside LI(Gyp LI)对肾透明细胞癌细胞增殖、凋亡和自噬的影响及其作用机制。方法采用网络药理学及分子对接技术预测有效成分与关键作用靶点的结合,对关键靶点和通路进行体外实验验证。利用CCK8实验检测Gyp L和Gyp LI对肾透明癌细胞ACHN和769-P的细胞活力的影响;采用Hoechst法检测Gyp L和Gyp LI对ACHN及769-P细胞凋亡的影响;利用荧光探针DCFH-DA检测Gyp L、Gyp LI对ACHN及769-P细胞内活性氧的影响;采用Westernblot法检测Gyp L、Gyp LI对蛋白激酶B(Akt)、哺乳动物雷帕霉素靶蛋白(mTOR)及其磷酸化的影响;并检测了自噬相关蛋白微管相关蛋白轻链3(LC3)、螯合体1(SQSTM1/p62)的表达水平。利用透射电镜检测自噬小体和自噬溶酶体。结果与对照组相比,Gyp L和Gyp LI显著抑制ACHN及769-P细胞增殖,且呈时间和浓度依赖性;与对照组相比,Gyp L和Gyp LI处理组细胞萎缩变小,并伴有凋亡小体形成;细胞凋亡率显著升高,自噬小泡堆积显著增多;与对照组相比,Gyp L和Gyp LI处理组LC3Ⅱ/LC3Ⅰ的表达显著升高,P62表达显著降低,p-Akt、p-mTOR的表达显著降低。透射电镜结果显示Gyp L和Gyp LI处理后的ACHN和769-P细胞,观察到明显的细胞自噬相关形态。结论Gyp L和Gyp LI可通过抑制Akt/mTOR通路抑制肾透明细胞癌细胞增殖并诱导其凋亡及自噬。 展开更多
关键词 Gypenoside L Gypenoside LI 肾透明细胞癌 自噬 AKT通路
暂未订购 下载PDF
T1期Ⅲ/Ⅳ级肾透明细胞癌术后复发转移的危险因素分析及手术方式对预后的影响 认领 引用
13
作者 吉剑波 陈浩楠 +8 位作者 袁甜甜 瞿兆奎 宋国新 鲍美玲 梁晓东 江波 王一洋 纪昊 李鹏超 《现代泌尿外科杂志》 CAS 2026年第1期12-16,共5页
目的探讨T1期高级别(Ⅲ/Ⅳ级)肾透明细胞癌(ccRCC)患者术后复发及转移的危险因素,分析手术方式对预后的影响,以期为临床实践提供预后评估与治疗方面的依据。方法回顾性分析2008年1月—2022年9月于江苏省人民医院泌尿科诊断为T1期Ⅲ/Ⅳ级... 目的探讨T1期高级别(Ⅲ/Ⅳ级)肾透明细胞癌(ccRCC)患者术后复发及转移的危险因素,分析手术方式对预后的影响,以期为临床实践提供预后评估与治疗方面的依据。方法回顾性分析2008年1月—2022年9月于江苏省人民医院泌尿科诊断为T1期Ⅲ/Ⅳ级ccRCC并行肾部分切除术(PN)或肾根治性切除术(RN)的398例患者的临床资料,按随访期内是否复发分为复发组(49例)和未复发组(349例),比较两组患者的一般资料、临床资料及预后情况。采用单因素和多因素Cox回归分析探究患者术后无病生存期(DFS)和总生存期(OS)的影响因素;利用Kaplan-Meier曲线分别对T1a和T1b期患者手术方式(PN/RN)进行亚组分析。结果398例患者的中位随访时间为67(42,98)个月,复发组较未复发组患者的年龄和肿瘤直径更大、T1b期患者占比更高且肿瘤解剖结构更复杂。单因素和多因素Cox回归分析均表明年龄≥55岁和R.E.N.A.L.评分≥7分是T1期Ⅲ/Ⅳ级RCC患者术后DFS和OS的独立危险因素(P<0.05)。亚组分析显示,PN或RN对T1a期患者的DFS、OS及T1b期患者的OS无明显影响,而RN对T1b期患者的DFS有显著生存获益(P<0.05)。结论年龄偏大、R.E.N.A.L.评分偏高的T1期高级别ccRCC患者更可能有较差的术后DFS和OS,对于T1b期患者,RN可能带来比PN更好的DFS。 展开更多
关键词 肾透明细胞癌 肾部分切除术 根治性肾切除术 无病生存期 总生存期
暂未订购 下载PDF
LncRNA SNHG16通过miR-506-3p调控肾透明细胞癌细胞增殖和转移的机制研究 认领 引用
14
作者 程涛 谷明利 +3 位作者 徐卫强 毛溧凯 胡兴邦 丁永辉 《河北医药》 CAS 2026年第2期181-186,共6页
目的 探讨长链非编码RNA(lncRNA)SNHG16靶向调控miR-506-3p对肾透明细胞癌(ccRCC)细胞增殖和转移的影响及作用机制。方法 通过ENCORI/starBase数据库预测SNHG16和PTBP1与miR-506-3p的结合位点。双萤光素酶报告基因系统及RNA免疫沉淀实... 目的 探讨长链非编码RNA(lncRNA)SNHG16靶向调控miR-506-3p对肾透明细胞癌(ccRCC)细胞增殖和转移的影响及作用机制。方法 通过ENCORI/starBase数据库预测SNHG16和PTBP1与miR-506-3p的结合位点。双萤光素酶报告基因系统及RNA免疫沉淀实验检测SNHG16和PTBP1与miR-506-3p的相互作用。qRT-PCR检测SNHG16在ccRCC细胞系(Caki-1、A498、ACHN、786-O和OSRC-2)和人正常肾皮质近曲小管上皮细胞(HK-2)中的表达及miR-506-3p和PTBP1 mRNA在A498细胞中的表达。靶向SNHG16的短发夹RNA(short hair RNA,shSNHG16)及阴性对照(shNC)、miR-506-3p inhibitor及阴性对照(NC inhibitor)、miR-506-3p mimic(miR-506-3p)及阴性对照(miR-NC)、过表达PTBP1的质粒(PTBP1)及对照空载体pcDNA3.1转染A498细胞建立敲低SNHG16和miR-506-3p及过表达miR-506-3p和PTBP1的细胞。细胞核质RNA分离实验确定SNHG16的亚细胞定位。CCK-8、EdU和Transwell实验分别检测A498细胞的增殖、迁移和侵袭能力。Western blot检测PTBP1的蛋白表达。结果 qRT-PCR结果显示,与正常细胞相比,SNHG16在ccRCC细胞中表达上调(P<0.05),且定位在细胞质中(P<0.05)。与shNC组相比,shSNHG16组A498细胞活力、增殖、迁移和侵袭能力均显著降低(P<0.05)。过表达miR-506-3p明显降低A498细胞中SNHG16-WT的荧光素酶活性(P<0.05),Ago2抗体可同时富集SNHG16和miR-506-3p(P<0.05)。过表达miR-506-3p可导致SNHG16表达下调(P<0.05)。干涉miR-506-3p可减弱shSNHG16转染对ccRCC细胞增殖、迁移和侵袭的抑制作用(P<0.05)。过表达miR-506-3p可抑制A498细胞中PTBP1-WT的荧光素酶活性及PTBP1的mRNA和蛋白表达水平(P<0.05)。过表达PTBP1则减弱了miR-506-3p对ccRCC细胞增殖、迁移和侵袭的抑制作用(P<0.05)。结论 SNHG16在ccRCC中表达上调,干涉SNHG16通过靶向调控miR-506-3p/PTBP1轴抑制ccRCC细胞的增殖和转移。 展开更多
关键词 LncRNA SNHG16 miR-506-3p 肾透明细胞癌细胞 增殖 转移
暂未订购 下载PDF
子宫囊性腺瘤样瘤合并卵巢透明细胞癌1例并文献复习 认领 引用
15
作者 马德晶 董景敏 +1 位作者 田燕 董立杰 《中国医学计算机成像杂志》 CSCD 北大核心 2026年第2期306-308,共3页
临床资料本文为回顾性研究,遵守《赫尔辛基宣言》,经滨州医学院附属医院伦理委员会批准(批准文号:KYLL-151),免除受试者知情同意.
关键词 囊性腺瘤样瘤 子宫 卵巢透明细胞癌 磁共振成像
暂未订购 下载PDF
肾透明细胞癌发生和发展中脂质代谢重编程的研究进展 认领 引用
16
作者 何紫微 董凯 王林辉 《海军军医大学学报》 CAS CSCD 北大核心 2026年第6期800-806,共7页
脂质代谢重编程是指肿瘤细胞通过调节代谢途径和基因表达适应能量供应和需求的变化,特别是在脂质合成、摄取和储存方面的调整。这种重编程通常涉及一系列复杂的分子机制,包括转录因子的活动、信号通路的激活以及代谢酶的表达变化。肾透... 脂质代谢重编程是指肿瘤细胞通过调节代谢途径和基因表达适应能量供应和需求的变化,特别是在脂质合成、摄取和储存方面的调整。这种重编程通常涉及一系列复杂的分子机制,包括转录因子的活动、信号通路的激活以及代谢酶的表达变化。肾透明细胞癌(ccRCC)是原发性肾细胞癌中最常见的亚型,癌细胞内脂质积累是其重要组织学特征。这种脂质异常堆积的现象与ccRCC癌内脂质代谢重编程机制关系密切,有利于满足ccRCC发生及发展的能量需求,提供氧化应激保护、调节免疫细胞功能以躲避免疫系统攻击,但其具体作用和相关机制尚不清楚。本文综述了ccRCC发生和发展中脂质代谢重编程的研究进展,为研究者提供新视角。 展开更多
关键词 肾肿瘤 肾透明细胞癌 脂质代谢 脂肪酸 胆固醇 细胞重编程
暂未订购 下载PDF
腹腔镜下肾部分切除术联合肾静脉重建在肾癌合并肾静脉分支癌栓中的应用 认领 引用
17
作者 孙洋洋 张天标 +3 位作者 郑涛 杨帆 黄珍林 张卫星 《中华实用诊断与治疗杂志》 2026年第6期548-551,共4页
目的探讨腹腔镜下肾部分切除术联合肾静脉重建治疗肾癌合并肾静脉分支癌栓的疗效及安全性。方法2022年1月—2025年1月郑州大学第一附属医院诊治肾癌合并肾静脉分支癌栓患者8例,均行腹腔镜下肾部分切除术联合肾静脉重建,记录患者肿瘤位... 目的探讨腹腔镜下肾部分切除术联合肾静脉重建治疗肾癌合并肾静脉分支癌栓的疗效及安全性。方法2022年1月—2025年1月郑州大学第一附属医院诊治肾癌合并肾静脉分支癌栓患者8例,均行腹腔镜下肾部分切除术联合肾静脉重建,记录患者肿瘤位置、肿瘤直径、癌栓位置、癌栓分级、手术时间、术中热缺血时间、术中出血量、术后住院时间、术后并发症、肿瘤切缘、病理分级。术后随访,记录患肾恢复情况、肿瘤复发情况。结果8例患者中肿瘤位于双侧3例,左侧3例,右侧2例,其中1例左侧孤立肾肾癌和1例右侧肾癌患者合并慢性肾功能不全;肿瘤直径2.1~4.5(3.75±0.74)cm;癌栓位于肾静脉分支,均为0a级。8例患者均保肾成功,双侧肾癌患者中2例行一期手术,1例行分期手术,余5例均为一期手术。手术时间为105~180(129.4±33.7)min,术中热缺血时间为19~30(22.88±3.34)min,术中出血量为50~100(70.00±21.38)mL,术后住院时间5~9(6.5±1.8)d。1例患者术后发生轻度漏尿,1例患者术后第3天下床活动后继发出血,给予相应治疗后恢复可。8例患者组织病理检查肿瘤切缘均为阴性,均为肾透明细胞癌,病理分级Ⅰ级1例,Ⅱ级7例。8例患者术后随访11~45个月,患肾血供良好、无萎缩、无尿瘘,均未见肿瘤复发。结论对于合并肾静脉分支癌栓的双侧肾癌、孤立肾肾癌、健侧肾功能不全单侧肾癌患者,腹腔镜下肾部分切除术联合肾静脉重建是一种可选择的保肾治疗方案,疗效较好,并发症可控。 展开更多
关键词 肾细胞癌 肾静脉分支癌栓 肾部分切除术 肾静脉重建 腹腔镜
暂未订购 下载PDF
T3a期肾非透明细胞癌手术患者远期预后影响因素分析及预测模型构建 认领 引用
18
作者 范振永 詹扬 +5 位作者 郭立刚 刘文健 梅国徽 王二朋 王海江 戴廷山 《转化医学杂志》 2026年第4期615-620,共6页
目的探讨行手术治疗T3a期肾非透明细胞癌患者远期预后的影响因素并构建其预测模型。方法回顾性选取2016年1月至2023年1月于阜阳市第二人民医院接受手术治疗的T3a期肾非透明细胞癌患者64例。绘制生存曲线,并比较不同临床特征亚组5年总生... 目的探讨行手术治疗T3a期肾非透明细胞癌患者远期预后的影响因素并构建其预测模型。方法回顾性选取2016年1月至2023年1月于阜阳市第二人民医院接受手术治疗的T3a期肾非透明细胞癌患者64例。绘制生存曲线,并比较不同临床特征亚组5年总生存率。采用Cox单因素及多因素分析筛选患者远期预后的独立影响因素,并进行预测模型构建及效能分析。结果64例患者中位随访时间为45.0个月,死亡13例,5年无进展生存率和总生存率分别为68.31%和71.82%;肿瘤最大径、术前乳酸脱氢酶水平、术前空腹血糖水平及是否存在肾静脉侵犯且无静脉壁侵犯患者的5年总生存率比较,差异有统计学意义(P<0.05)。Cox比例风险回归结果显示,肿瘤最大径较大、术前乳酸脱氢酶水平高及存在肾静脉侵犯且无静脉壁侵犯均是行手术治疗T3a期肾非透明细胞癌远期预后独立危险因素(P<0.05)。基于上述独立影响因素构建的列线图模型,对训练集1年、3年、5年生存结局预测的曲线下面积分别为0.783、0.741、0.748;对验证集1年、3年、5年生存结局预测的曲线下面积分别为0.880、0.851、0.808。结论行手术治疗T3a期肾非透明细胞癌患者远期预后与肿瘤大小、术前乳酸脱氢酶水平及周围组织侵犯情况有关;基于上述因素构建列线图模型在预测患者术后生存结局方面显示出良好效能。 展开更多
关键词 肾细胞癌 非透明细胞癌 手术 远期预后 影响因素 总生存时间
暂未订购 下载PDF
晚期透明细胞肾细胞癌患者接受贝莫苏拜单抗联合安罗替尼治疗获得长期生存1例 认领 引用
19
作者 田惠春 张佳冉 李娟 《北京大学学报（医学版）》 CAS CSCD 北大核心 2026年第4期865-871,共7页
透明细胞肾细胞癌(clear cell renal cell carcinoma,ccRCC)是肾细胞癌最常见的病理类型,国际转移性肾癌数据库联盟(International Metastatic Renal Cell Carcinoma Database Consortium,IMDC)中高危患者,尤其伴多器官转移者预后较差... 透明细胞肾细胞癌(clear cell renal cell carcinoma,ccRCC)是肾细胞癌最常见的病理类型,国际转移性肾癌数据库联盟(International Metastatic Renal Cell Carcinoma Database Consortium,IMDC)中高危患者,尤其伴多器官转移者预后较差。本文报道1例IMDC高危晚期ccRCC患者,男性,65岁,行右肾癌根治术后短期内出现肺、肝及骨多发转移,伴贫血、中性粒细胞及血小板升高,IMDC评分5分。患者接受贝莫苏拜单抗联合安罗替尼一线治疗,治疗6周后影像学评估即达到部分缓解(partial response,PR),后续多次复查持续维持PR,肿瘤总体缩小约48%,临床症状明显改善。治疗过程中患者出现进行性蛋白尿,经安罗替尼逐步减量后仍反复出现,最终停用靶向治疗后蛋白尿明显缓解。停用安罗替尼后患者继续接受贝莫苏拜单抗单药维持治疗,疾病持续维持深度缓解。治疗约3年后患者出现血肌酐升高,最高达228μmol/L,综合考虑肾损伤及疾病稳定状态后停用免疫治疗。此后未再接受抗肿瘤治疗,直至2024年9月疾病进展并死亡,总生存期达44个月。本病例提示,在IMDC高危晚期ccRCC患者中,贝莫苏拜单抗联合安罗替尼可实现快速且持久的抗肿瘤效应,对联合治疗敏感的患者,在发生不可耐受不良反应时停用酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs),并转为免疫单药维持治疗,仍可能获得长期疾病控制,其机制可能与抗血管生成治疗诱导的肿瘤免疫微环境重塑及免疫记忆效应有关。本病例同时提示,在靶向联合免疫治疗过程中应重视肾毒性监测,并进行个体化治疗调整。 展开更多
关键词 肾透明细胞癌 免疫治疗 靶向治疗
暂未订购 下载PDF
纳武利尤单抗治疗转移性肾透明细胞癌的效果及对患者肿瘤微环境的影响 认领 引用
20
作者 张群妹 狄文玉 +2 位作者 张春晓 王海峰 鲁广建 《实用癌症杂志》 2026年第1期151-154,共4页
目的探讨纳武利尤单抗在转移性肾透明细胞癌治疗中的效果及安全性。方法该研究为一项前瞻性、随机对照试验,共纳入118例转移性透明细胞癌患者。随机将患者分为观察组(纳武利尤单抗组,59例)和对照组(依维莫司组,59例),比较2组治疗效果和... 目的探讨纳武利尤单抗在转移性肾透明细胞癌治疗中的效果及安全性。方法该研究为一项前瞻性、随机对照试验,共纳入118例转移性透明细胞癌患者。随机将患者分为观察组(纳武利尤单抗组,59例)和对照组(依维莫司组,59例),比较2组治疗效果和不良反应发生情况。同时,通过流式细胞术分析肿瘤微环境中CD8+T细胞和Treg细胞的比例。结果观察组的客观缓解率和疾病控制率显著高于对照组(P<0.001),且不良反应发生率低于对照组(32.2%vs 50.8%,P=0.040)。肿瘤微环境分析显示,观察组的CD8+T细胞比例显著高于对照组,而Treg细胞比例则显著低于对照组(P<0.001)。结论纳武利尤单抗在转移性透明细胞癌治疗中的效果显著优于依维莫司,且具有更好的耐受性,同时在改善肿瘤微环境方面纳武利尤单抗表现出更显著的优势。 展开更多
关键词 转移性肾透明细胞癌 纳武利尤单抗 依维莫司 免疫疗法 肿瘤微环境
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 91 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈